OncoMatch/Clinical Trials/NCT05564390
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Is NCT05564390 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for acute myeloid leukemia.
Treatment: Azacitidine · Busulfan · Cytarabine · Daunorubicin Hydrochloride · Decitabine and Cedazuridine · Emavusertib · Enasidenib · Epoetin Alfa · Fludarabine · Gemtuzumab Ozogamicin · Gilteritinib · Liposome-encapsulated Daunorubicin-Cytarabine · Luspatercept · Melphalan · Olutasidenib · Venetoclax — This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Prior therapy
Cannot have received: anti-cancer therapy
Exception: hydroxyurea to control WBC is allowed; prior erythroid stimulating agent is not considered prior therapy; up to 1 g/m^2 cytarabine for urgent cytoreduction is allowed
Participants must not have received prior anti-cancer therapy for AML or MDS. Note: Hydroxyurea to control the white blood cell count (WBC) is allowed. Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m^2 of cytarabine, which is allowed for urgent cytoreduction.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- Mayo Clinic Hospital in Arizona · Phoenix, Arizona
- Banner University Medical Center - Tucson · Tucson, Arizona
- University of Arizona Cancer Center-North Campus · Tucson, Arizona
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify